Avenue Therapeutics, Inc. has formally requested the Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3. The company, based in Bay Harbor Islands, Florida, submitted the request via EDGAR on May 8, 2024, with the desired effective date being 4:00 p.m. Eastern time on May 10, 2024, or as soon as possible thereafter. The request was made under Rule 461 of the Securities Act of 1933, as amended. Avenue Therapeutics has authorized Rakesh Gopalan and David S. Wolpa, attorneys from its outside legal counsel Troutman Pepper Hamilton Sanders LLP, to modify or withdraw the acceleration request if necessary. The company has asked the SEC to confirm the Registration Statement's effective status with its legal representatives upon approval.

Avenue Therapeutics, Inc. has formally requested the Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3. The company, based in Bay Harbor Islands, Florida, submitted the request via EDGAR on May 8, 2024, with the desired effective date being 4:00 p.m. Eastern time on May 10, 2024, or as soon as possible thereafter. The request was made under Rule 461 of the Securities Act of 1933, as amended. Avenue Therapeutics has authorized Rakesh Gopalan and David S. Wolpa, attorneys from its outside legal counsel Troutman Pepper Hamilton Sanders LLP, to modify or withdraw the acceleration request if necessary. The company has asked the SEC to confirm the Registration Statement's effective status with its legal representatives upon approval.